Pramelix Therapeutics

Pramelix Therapeutics is a biotechnology company focused on developing novel peptide-based therapies for metabolic diseases, with a primary emphasis on obesity and type 2 diabetes. The company is advancing a pipeline of long-acting amylin analogs designed to improve weight loss outcomes and metabolic health. Their lead candidate is engineered to provide sustained activation of the amylin receptor, offering a potentially differentiated mechanism compared to or in combination with GLP-1 based therapies. Pramelix was founded by experienced industry leaders and is backed by prominent life science investors like Atlas Venture. The company aims to address the significant unmet need in the global obesity epidemic through precision peptide engineering and optimized pharmacokinetics.